Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Imunoinstant G is a dietary supplement developed by the Romanian company Romvac Company under the Imunoinstant brand. It is a lyophilized powder containing polyclonal IgY antibodies (immunoglobulin Y) extracted from the egg yolks of hyperimmunized hens. The product is designed to provide passive immune support by delivering specific antibodies that target and neutralize a broad spectrum of bacterial, viral, and fungal pathogens. By binding to these pathogens, the IgY antibodies prevent their attachment to mucosal surfaces and neutralize their activity, thereby supporting the body's natural defense mechanisms against infections. It is typically administered orally and is marketed for the management and prevention of various infectious conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Imunoinstant G.